pregabalin / Generic mfg. - LARVOL DELTA

Liquiritin attenuates IONI-induced trigeminal neuropathic pain via TLR4/MyD88-dependent modulation of microglial M1-like polarization. (PubMed, Int Immunopharmacol) - "Liquiritin alleviated IONI-induced TN-like neuropathic pain in mice, concomitant with reduced microglial M1-like activation, decreased IL-1β/TNF-α and TRPV1/CGRP levels, and down-regulation of TLR4/MyD88 signaling in trigeminal tissues. These in vivo, in vitro and in silico data support Liquiritin as a promising neuroinflammation-modulating candidate targeting TLR4/MyD88 in trigeminal neuropathic pain, warranting further pharmacokinetic, long-term safety and translational studies."

IO biomarker • Journal • Inflammation • Neuralgia • Pain • FCGR2A • FCGR2B • IL1B • MYD88 • TLR4 • TNFA • TRPV1

Placebo and nocebo responses in gabapentin enacarbil and pregabalin trials for restless legs syndrome: time-course model-based network meta-analysis and meta-analysis of proportions. (PubMed, Sleep Breath) - No abstract available

Journal • Retrospective data • Review • Movement Disorders • Restless Legs Syndrome • Sleep Disorder

LONG-TERM OPIOID AND GABAPENTINOID RELATED HARMS AMONG ADULTS WITH CHRONIC KIDNEY DISEASE: A TIME-UPDATED, POPULATION-BASED COHORT STUDY (ISN-WCN 2026) - "The most frequently prescribed opioid items were co-codamol, tramadol and codeine (4,055, 2,075 and 1,236 prescriptions, respectively) whilst gabapentin was prescribed more often than pregabalin (1,273 vs 742 prescriptions). Cumulative gabapentinoid use is not associated with death in such patients. This abstract was also submitted for the Scottish Renal Association meeting as permitted."

Clinical • Addiction (Opioid and Alcohol) • Chronic Kidney Disease • CNS Disorders • Depression • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Respiratory Diseases

DIFELIKEFALIN USE IN HAEMODIALYSIS RECIPIENTS WITH GABAPENTINOID-REFRACTORY CHRONIC KIDNEY DISEASE ASSOCIATED PRURITUS (ISN-WCN 2026) - "2 patients experienced relapses in itch (WI-NRS increase of >3-points after initial >3-point reduction) and were diagnosed with conditions unrelated to CKDaP, and itch resolved after appropriate alternate treatments.Download: Download high-res image (232KB)Download: Download full-size imageFigure 1. Worse-Itch Numerical Rating Scale (WI-NRS) after initiation of DifelikefalinConclusion Difelikefalin is an effective and well-tolerated treatment for CKDaP in patients who have failed treatment with gabapentin or pregabalin, therefore providing a useful therapeutic option for refractory cases of CKDaP.I have potential conflict of interest to disclose.Dr Li has received honoraria from CSL Seqirus.I did not use generative AI and AI-assisted technologies in the writing process."

Alzheimer's Disease • Chronic Kidney Disease • Cognitive Disorders • Dermatology • Movement Disorders • Nephrology • Pruritus • Renal Disease • Restless Legs Syndrome • Sleep Disorder

EFFICACY OF SUBCUTANEOUS LIDOCAINE INFUSION FOR CKD-ASSOCIATED PRURITUS (CKD-AP) (ISN-WCN 2026) - "Furthermore, CKM patients have difficulty accessing intravenous difelikefalin, which is only approved for haemodialysis patients...Other skin conditions were excluded following dermatology review and multiple therapies had been trialled, including regular aqueous emollients, topical capsaicin, pregabalin (up to doses of 150mg BD), methylprednisone 0.1% ointment, sertraline, evening primrose oil and doxepin...No side-effects were observed. The response was sustained for 6 weeks, after which the patient deteriorated from underlying kidney failure and end of life care was provided.Conclusion Subcutaneous lidocaine infusion may be an effective and safe alternative treatment option for cases of refractory CKD-aP.I have potential conflict of interest to disclose.Dr Kelly Li receives honoraria from CSL SeqirusI did not use generative AI and AI-assisted technologies in the writing process."

Clinical • Alzheimer's Disease • Chronic Kidney Disease • CNS Disorders • Dementia • Depression • Dermatology • Diabetic Nephropathy • Insomnia • Nephrology • Pruritus • Sleep Disorder

Utility and sensitivity of wett-SA53 to measure dysgeusia associated with talquetamab, a GPRC5D×CD3 bispecific antibody, in Relapsed/Refractory multiple myeloma: Preliminary data from the talisman study (ASH 2025) - P2 | "Experimental prophylaxes include dexamethasone [Dex] mouthwash, oral pregabalin, orclonazepam orally dissolving tablets. In this randomized, phase 2 study utilizing the WETT SA-53 assessment tool for the first timein pts with MM, WETT scores appeared to be highly sensitive with the ability to objectively capture abroader spectrum of taste changes throughout Tal treatment compared with CTCAE grading. Preliminarydata showed the WETT scale was able to detect dysgeusia, and importantly, objective improvements indysgeusia by cycle 8. Results from this study will help characterize and guide management of dysgeusiaassociated with GPRC5D treatment and may establish the WETT assessment as an important objectivetool for cancer agents impacting taste."

IO biomarker • Dental Disorders • Hematological Malignancies • Mucositis • Multiple Myeloma • Stomatitis • Xerostomia

Early effects of scheduling gabapentin on medication adherence among epilepsy patients on gabapentin in Virginia. (PubMed, Int J Drug Policy) - "In the six months following Virginia's policy change, scheduling gabapentin was associated with a decline in the proportion of days covered among epilepsy patients. Given ongoing state-level gabapentin policy changes, continued research on the impacts of scheduling gabapentin on patient care and barriers to medication access is warranted."

Journal • CNS Disorders • Epilepsy

Gabapentinoids and unexplained death in general practice: Case series and feasibility study arising from a critical incident. (PubMed, Eur J Gen Pract) - "Patient, practice and health-system related factors need to be addressed in relation to gabapentinoid associated deaths and reflected in clinical practice guidelines. There is critical value in using toxicology reports from Coroner's offices in cases of unexplained gabapentinoid death in general practice."

Journal • Addiction (Opioid and Alcohol)

Neuropathic Pain Medications and Their Impact on Body-Focused Repetitive Behaviors in Patients with Cervical Spine Disorders: A Cross-Sectional Analysis (AAD 2026) - "Although response to N-acetylcysteine (11%) was poor, pregabalin (100%), gabapentin (67%), HRT (67%), SNRIs (60%), and amitriptyline (50%) observed greater positive response rates. In addition to highlighting C-spine diseases as notable comorbidities for BFRBs, this study suggests that combining neuropathic medications with behavioral therapy may offer an optimal treatment strategy for these patients. By emphasizing early detection and management of C-spine pathology, this approach provides a comprehensive framework, addressing potential anatomical contributors and improving overall therapeutic outcomes."

Clinical • Behavior Disorders • Mental Retardation • Neuralgia • Obsessive-Compulsive Disorder • Pain • Pruritus

Targeting Orofacial Pain: From Pathophysiological Mechanisms to Traditional Chinese Medicine Approaches. (PubMed, Behav Brain Res) - "Current drugs, including carbamazepine and pregabalin, offer only partial relief and are limited by adverse effects, underscoring the need for alternative therapeutic strategies. Finally, we highlight challenges-such as standardization, biomarker-guided diagnostics, and the lack of large-scale clinical trials-and propose future directions. By linking traditional insights with contemporary neuroscience, this review aims to provide a mechanistic framework for effective, personalized, and sustainable therapies."

Journal • Review • Inflammation • Pain

Pregabalin efficacy in painful diabetic peripheral neuropathy: A focused analysis of optimal dosing and the relationship of baseline glycemic control. (PubMed, J Diabetes Investig) - "Pregabalin at 300 and 600 mg/day provides significant pain relief in pDPN, regardless of HbA1c levels, supporting dose optimization to achieve maximal benefit."

Clinical • Journal • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Pain • Peripheral Neuropathic Pain

Thermotolerant D-Hydantoinases for Efficient and Stereoselective Intermediate Synthesis of (R)-3-Isobutylglutaric Acid Monoamide, a Key Intermediate in Pregabalin Production. (PubMed, Microb Biotechnol) - "The enantiomeric excess (ee%) of R-IBM improved from 73.74% to 97.55% for GsDHTase, 56.08% to 97.59% for AcDHTase and 78.32% to 96.85% for BhDHTase after mutation. Owing to their inherent robustness, these enzymes hold great potential for developing a theoretical 100% atom-economical route for the eco-friendly and cost-effective industrial production of pregabalin."

Journal • CNS Disorders • Epilepsy • Neuralgia • Pain

Effect of Pregabalin on the Postoperative Analgesia in RFA of Focal Lesions in the Liver (clinicaltrials.gov) - P4 | N=70 | Completed | Sponsor: Sherief Abd-Elsalam | N=100 ➔ 70

Enrollment change • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

COMPREHENSIVE PAIN MANAGEMENT IN PAEDIATRIC ALLOGENIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): RETROSPECTIVE AUDIT OF SPECIALIST PAIN TEAM REFERRALS AND DEVELOPMENT OF A PILOT PAIN-MANAGEMENT PATHWAY (EBMT 2026) - "All three patients were high-risk HSCT for relapsed/refractory acute leukaemia (and developed severe acute complications in the immediate post-HSCT period (grade IV GVHD, grade III VOD with GI bleeding post defibrotide and fatal grade IV VOD).Table 1: Characteristics of patients referred to pain services*Both patients received post-transplant cyclophosphamide (PTCy)**mismatched cord HSCT for high-risk paediatric AML Better, more focused management of pain, using novel pharmacological and non-pharmacological measures, can improve the HSCT experience for children, and specialist pain management services and dedicated guidance are vital. Better, more focused management of pain, using novel pharmacological and non-pharmacological measures, can improve the HSCT experience for children, and specialist pain management services and dedicated guidance are vital. Regular paracetamol can be safely used as an analgesic without masking sepsis. Use of Pregabalin is safe in the..."

Retrospective data • Bone Marrow Transplantation • CNS Disorders • Gastrointestinal Disorder • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Mucositis • Pain • Pediatrics • Septic Shock • Sickle Cell Disease • Transplantation

COMPREHENSIVE PAIN MANAGEMENT IN PAEDIATRIC ALLOGENIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): RETROSPECTIVE AUDIT OF SPECIALIST PAIN TEAM REFERRALS AND DEVELOPMENT OF A PILOT PAIN-MANAGEMENT PATHWAY (EBMT 2026) - "All three patients were high-risk HSCT for relapsed/refractory acute leukaemia (and developed severe acute complications in the immediate post-HSCT period (grade IV GVHD, grade III VOD with GI bleeding post defibrotide and fatal grade IV VOD).Table 1: Characteristics of patients referred to pain services*Both patients received post-transplant cyclophosphamide (PTCy)**mismatched cord HSCT for high-risk paediatric AML Better, more focused management of pain, using novel pharmacological and non-pharmacological measures, can improve the HSCT experience for children, and specialist pain management services and dedicated guidance are vital. Better, more focused management of pain, using novel pharmacological and non-pharmacological measures, can improve the HSCT experience for children, and specialist pain management services and dedicated guidance are vital. Regular paracetamol can be safely used as an analgesic without masking sepsis. Use of Pregabalin is safe in the..."

Retrospective data • Bone Marrow Transplantation • CNS Disorders • Gastrointestinal Disorder • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Mucositis • Pain • Pediatrics • Septic Shock • Sickle Cell Disease • Transplantation

Cyclobenzaprine Reimagined: Clinical Insights Into Tonmya for Fibromyalgia. (PubMed, J Pharm Technol) - " Pharmacologic agents receive a weak recommendation for use in the treatment guidelines and include agents such as duloxetine, pregabalin, tramadol, amitriptyline, and a nonsublingual formulation of cyclobenzaprine. Tonmya, the newest agent approved for fibromyalgia, provides clinicians with an additional treatment option in a convenient dosage form for this potentially debilitating condition."

Journal • Review • Fibromyalgia • Musculoskeletal Pain • Pain • Rheumatology

Neuroprotective effects of pregabalin in experimental spinal cord injury: An investigation of oxidative stress and antioxidant enzymes in blood and neural tissue. (PubMed, Ulus Travma Acil Cerrahi Derg) - "Pregabalin mitigated oxidative stress and partially improved functional stability in experimental spinal cord injury, suggesting possible clinical applicability pending further validation."

Journal • CNS Disorders • Orthopedics

Spontaneous Onset of Postoperative Chilaiditi Syndrome: A Case Report and Its Potential Other Association? (PubMed, J Med Cases) - "The patient had been prescribed pregabalin as part of the treatment for her psychiatric conditions...There is an established link which already exists, but the reasons as to why this exists are yet to be cemented. Similarly, few cases of Chilaiditi syndrome developing in the perioperative setting have been reported, so this case is valuable in considering the role of anesthetics and postoperative analgesia in the development of this syndrome."

Journal • Anesthesia • Cardiovascular • CNS Disorders • Constipation • Depression • Gastroenterology • Gastrointestinal Disorder • General Anxiety Disorder • Immunology • Musculoskeletal Diseases • Orthopedics • Osteoarthritis • Pain • Psychiatry • Pulmonary Embolism • Respiratory Diseases • Rheumatology

A Prospective, Multicenter, Single-arm, Phase IV Study to Assess the Safety and Effectiveness of a Fixed-Dose Combination of Pregabalin Prolonged Release and Etoricoxib in Patients with Chronic Low Back Pain with a Neuropathic Component. (PubMed, Drugs Real World Outcomes) - "The FDC of pregabalin PR and etoricoxib was found to be safe, well tolerated, and effective in reducing pain intensity and improving quality of life in patients with CLBP with a neuropathic component. Thus, this FDC can be a potential alternative for managing CLBP with a neuropathic component."

Journal • P4 data • Back Pain • Cough • Dermatology • Lumbar Back Pain • Musculoskeletal Pain • Neuralgia • Pain • Pruritus • Respiratory Diseases

Pregabalin in an Older Adult Man With Treatment-Resistant Catatonia: A Case Report. (PubMed, J Clin Psychopharmacol) - No abstract available

Journal

Author's Response to Letter to the Editor Regarding "Efficacy and Safety of Once-Daily Prolonged-Release Pregabalin for the Treatment of Patients With Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, Active, and Placebo-Controlled Trial". (PubMed, Pain Pract) - No abstract available

Clinical • Journal • Diabetic Neuropathy • Pain

Combination therapy with pregabalin and thioctic acid offers safer pain control in diabetic neuropathy: a multicenter, double-blind, non-inferiority trial. (PubMed, Brain Commun) - "A fixed-dose combination of low-dose pregabalin and thioctic acid is non-inferior to high-dose pregabalin for analgesic efficacy and demonstrates an improved safety profile. These findings support this combination as a safe and better-tolerated treatment alternative for painful diabetic peripheral neuropathy."

Clinical • Head-to-Head • Journal • Diabetic Neuropathy • Neuralgia • Pain • Peripheral Neuropathic Pain • Xerostomia

Prescription Trends and Clinical Decision-Making in Neuropathic Pain Pharmacological Treatment: Results From a Cross-Sectional Survey by the Spanish Pain Society. (PubMed, Eur J Pain) - "This nationwide survey provides the first systematic assessment of neuropathic pain management in Spain, revealing marked variability, only partial adherence to international guidelines, and persistent reliance on clinical experience over evidence. It confirms gabapentinoids, tricyclic antidepressants and duloxetine as preferred treatments, identifies continued tramadol use despite conflicting recommendations, and quantifies for the first time clinicians' perception and management of tolerance. These findings fill a major evidence gap and directly inform future national consensus, educational initiatives and clinical practice improvement."

Journal • Neuralgia • Pain

Nanocomposite hydrogel acupoint therapy for sustained pregabalin delivery and long-term neuropathic pain relief. (PubMed, Mater Today Bio) - "In rat models of paclitaxel-induced neuropathy and chronic constriction injury, acupoint administration of PG@PLGA-gels significantly mitigates mechanical and cold allodynia from day 8 to day 20, while no obvious sedation-related behaviors were observed. Transcriptomic analysis identified treatment-associated changes in spinal cord gene expression profiles, with enrichment in pathways related to neuronal structure, synaptic organization, excitatory signaling, and neuroendocrine regulation. Together, these results support PG@PLGA-gels as an acupoint nanomedicine platform that combines controlled drug delivery with acupoint-based modulation to achieve prolonged analgesia with minimized adverse effects."

Journal • Anesthesia • Neuralgia • Pain

Mind and Muscle: A Retrospective Study on the Management of Psychiatric Comorbidities in Patients With Fibromyalgia Treated With Pregabalin Versus Milnacipran. (PubMed, Cureus) - " Overall, differences observed between groups may not be clinically significant. This information may help clinicians and patients employ well-informed, shared decision-making."

Journal • Retrospective data • CNS Disorders • Depression • Fatigue • Fibromyalgia • Mood Disorders • Musculoskeletal Pain • Pain • Psychiatry • Rheumatology • Substance Abuse